Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia

• Published in: Human vaccines & immunotherapeutics Vol. 12; no. 11; pp. 2953 - 2958
• Main Authors: Vila-Corcoles, Angel, Ochoa-Gondar, Olga, Hospital, Imma, de Diego, Cinta, Satué, Eva, Bladé, Jordi, Ansa, Xabier, Guzmán, Jorge A., Salsench, Elisabet, Ramos, Francisca
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.11.2016
• Subjects: adults; Aged; Aged, 80 and over; coverage; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; pneumococcal conjugate vaccine; Pneumococcal Infections - epidemiology; Pneumococcal Infections - prevention & control; pneumococcal polysaccharide vaccine; pneumococcal vaccination; Pneumococcal Vaccines - administration & dosage; Research Papers; Risk Assessment; Spain - epidemiology; Vaccination - utilization; coverage; pneumococcal vaccination; pneumococcal polysaccharide vaccine; adults; pneumococcal conjugate vaccine
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2016.1210744

There is scarce data about pneumococcal vaccination coverages among adults in recent years. We investigated current pneumococcal vaccination coverages in Catalonia, Spain, with a cross-sectional population-based study including 2,033,465 individuals aged 50 y or older assigned to the Catalonian Health Institute at 01/01/2015 (date of survey). A previously validated institutional research clinical Database was used to classify study subjects by their vaccination status for both 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), to identify comorbidities and underlying conditions, and establish the risk stratum of each individual: High risk stratum: functional or anatomic asplenia, cochlear implants, CSF leaks, or immunocompromising conditions; medium risk stratum: immunocompetent persons with history of chronic cardiac or respiratory disease, liver disease, diabetes mellitus, alcoholism and/or smoking; low risk stratum: persons without high or medium risk conditions. Of the total 2,033,465 study population, an amount of 789,098 (38.8%) had received PPVS23, whereas 5031 (0.2%) had received PCV13. PPSV23 coverages increased largely with increasing age: 4.8% in 50-59 y vs 35.5% in 60-69 y vs 71.9% in 70-79 y vs 79.5% in 80 y or older; p < 0.001). PCV13 coverages also increased with age, although they were very low in all age groups. PPSV23 coverages were 59.2% in high risk stratum, 48.3% in medium risk stratum and 28.1% in low risk stratum (p < 0.001). For the PCV13, uptakes were 1.2%, 0.3% and 0.1% in high, medium and low stratum, respectively (p < 0.001). In conclusion, pneumococcal vaccination coverages in Catalonian adults are not optimal, being especially small for the PCV13 (even in high-risk subjects).